Abstract
Objective:
Targeted screening for glucose-6-phosphate dehydrogenase deficiency (G6PDdef) using fluorescent spot test (FST) is done in our newborn nursery (NN) and now in our NICU. Premature infants have higher G6PD levels than term infants. FST may result in under diagnosis of G6PDdef in preterms. We sought to determine if FST is appropriate for diagnosis of G6PDdef at<35 weeks and assess screening in NICU.
Study Design:
Retrospective chart review of male, inborn infants<35 weeks in NICU from 2008 to 2011. Difference in G6PDdef incidence<5% between NN and NICU was acceptable for equivalence.
Results:
Out of 679 subjects, 442 were screened for G6PDdef and 11.3% had abnormal results. Binomial testing comparing 11.3% (95% confidence interval (CI) 8.5 to 14.6) incidence of G6PDdef in NICU and reported incidence in NN (11%) demonstrated no difference. 12.2% of Black/African American males were not screened.
Conclusion:
FST is appropriate for screening all at-risk newborns. A number of at-risk premature males were not screened.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nikhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E . The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cell Mol Dis 2009; 42: 267–278.
WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Org 1989; 67: 601–611.
Bhutani VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004; 24: 650–662.
Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN . International committee of standardization in haematology: recommneded screening test for gluose-6-phosphate dehydroganase (G-6-PD) deficiency. Brit J Haematol 1979; 43: 465–467.
Wolf BHM, Weening RS, Schutgens RBH, van Noorden CJF, Vogels IMC, Nagelkerke NJD . Detection of glucose-6-phosphate dehydrogenase deficiency in erythrocytes: a spectrophotometric assay and a fluorescent spot test compared with a cytochemical method. Clin Chim Acta 1987; 168: 129–136.
Roca-Felterer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A et al. Field trial evaluation of the performance of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS One 2014; 9: e116143.
Kaplan M, Leiter C, Hammerman C, Rudensky B . Comparison of commercial screening tests for glucose-6-phosphate dehydrogenase deficiency in the newborn period. Clin Chem 1997; 43: 1236–1237.
Nock ML, Johnson EM, Di Fiore JM, Fitzgerald S, Sandhaus LM, Walsh MC . Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol 2011; 31: 112–117.
Ainoon O, Alawiyah A, Yu YH, Cheong SK, Hamidah NH, Boo NY et al. Semiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partial-deficiency females. Southeast Asian J Trop Med Public Health 2003; 34 (2): 405–414.
Ko CH, Wong RP-O, Ng PC, Li K, Chui KM, Yuen PM-P et al. Oxidative challenge and glucose-6-phosphate dehydrogenase activity of preterm and term neonatal red blod cells. Neonatology 2009; 96: 96–101.
Mesner O, Hammerman C, Goldschmidt D, Rudensky B, Bader D, Kaplan M . Glucose-6-phosphate dehydrogenase activity in male premature and term neonates. Arch Dis Child Fetal Neonatal Ed 2004; 89: F555–F557.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Clinical practice guideline: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114 (1): 297–316.
Watchko JF, Maisels MJ . Enduring controversies in the management of hyperbilirubinemia in preterm neonates. Semin Fetal Neonat Med 2010; 15: 136–140.
Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK . Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? J Perinatol 2013; 33: 499–504.
Kaplan M, Beutler E, Vreman HJ, Hammerman C, Levy-Lahad E, Renbaum P et al. Neonatal hyperbilirubinemia in glucose-6-phosphate deydrogenase-deficient heterozygotes. Pediatrics 1999; 104: 68–74.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lam, R., Li, H. & Nock, M. Assessment of G6PD screening program in premature infants in a NICU. J Perinatol 35, 1027–1029 (2015). https://doi.org/10.1038/jp.2015.129
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2015.129